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Differential diagnosis between pancreatic cancer and chronic pancreatitis is still difficult to establish. In
63 patients with suspected pancreatic neoplasm we performed: serum CA 19-9 assessment, abdominal
ultrasound, CT scan and CT-guided pancreatic percutaneous fine-needle biopsy. The conclusive diagnosis
was pancreatic cancer in 40 patients and chronic pancreatitis in 23 patients. With regard to the differential
diagnosis, sensitivity and specificity were respectively 80% and78% for serum CA 19-9, 75% and 65% for
abdominal US, 85% and 70% for CT scan, 00% and 87% for percutaneous fine-needle biopsy. We
conclude that CT-guided percutaneous fine-needle biopsy is the most reliable method for differential
diagnosis between pancreatic cancer and chronic pancreatitis.
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INTRODUCTION
Differential diagnosis between pancreatic cancer and chronic pancreatitis is still
difficult to establish today despite the increasingly widespread use of tumors
markers1’2’3 and the recent progress made in the field of instrumental diagnosis.
Large scale use of ultrasonography (US) and computerized tomography (CT) has
actually worsened the situation by bringing to light more cases of focal pancreatic
lesions which are more or less asymptomatic4; it is not easy to establish if these lesions
are due to inflammation or a neoplasm. Pancreatic percutaneous fine-needle biopsy
5678 has recently been utilized more in the diagnostic field due to improvements in
the needles and the type of guide used9.
The aim of this study is to evaluate the contribution made by CT guided pancreatic
percutaneous fine-needle biopsy to differentiate between pancreatic cancer and
chronic pancreatitis.
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Results obtained with fine-needle biopsy were compared to those obtained with
CA 19-9 assay and with non invasive techniques (US, CT).
MATERIALS AND METHODS
Between December ’84 and March ’88,106 patients were admitted to our hospital for
suspected pancreatic neoplasm. 43 patients were excluded from this study as they
were discovered to have non pancreatic pathology. The remaining 63 patients, 37
male and 26 female, average age 61 years, range 32-83 years, with a final diagnosis
of pancreatic cancer or chronic pancreatitis were included in this study.
24 patients were jaundiced (19 with pancreatic cancer and 5 with chronic
pancreatitis). In all patients a focal pancreatic lesion was observed; the average
diameter of the punctured lesion was 4,4 cm, range 2-8 cm; the lesion was located in
39 patients in the head of the pancreas, in 18 in the body and in the remaining 6 in the
tail.
All the patients were subjected to the following diagnostic procedures:
-serum CA 19-9 assay by an immunoradiometric technique (Centocor- Sorin
Biomedica, Saluggia VC, Italy); a cut-off value of 40 U/ml was applied1.
-abdominal US, using 3,5 and 5 MHz probes.
-abdominal CT carried out with third generation model after rapid intravenous
injection of the contrast medium; 10 mm axial scans were done, and 5 mm scans in
the areas of most interest.
The images obtained from these procedures were examined by a staff radiologist
without knowledge of the cases, and classified either as positive for neoplasm,
negative for neoplasm or non-diagnostic.
During the CT scanning, pancreatic percutaneous fine-needle biopsy was
performed. After the exact localization of the lesion and the decision about the best
area for cytological examination, the exact spot of the scan was marked on the skin
with the luminous collimator of the CT gantry and subsequently the needle was
inserted, after local anaesthetization. Most specimens were taken with Chiba or
Franzen 22 G needles. The sample was drawn percutaneously and anteriorly. The
obtained smears were immediately fixed in an alcohol-ether solution, rapidly stained
with haematoxylin-eosin and immediately examined by the pathologist. When the
material was inadequate, another sample was taken using larger needles (20 G). An
average of 1,5 specimens was taken, range 1-3. The final results were expressed as
either positive for malignant tumor cells (MTC), negative for MTC or inadequate
material. After fine-needle biopsy all the patients were given aCT scan to ensure that
there were no blood clots. In the following days the patients were given a clinical
examination and analyses were carried out (determination of amylase in the serum
and urine) to exclude the onset of pancreatitis.
Of the 63 patients 35 (55%) underwent surgery, duringwhichwe looked for lesions
which could possibly be due to percutaneous fine-needle aspiration. A conclusive
diagnosis was made in these 35 patients by histological examination of the surgical
specimen (10 cases) or by cytological examination of the intraoperative pancreatic
fine-needle biopsy (25 cases). In all cases this biopsy confirmed the pre-operative CT-
guided pancreatic fine-needle biopsy; an average of 3 specimens was taken, range 1-
6. In the remaining 28 patients (45%) who did not have surgery, the conclusive
diagnosis was made by means of the aforesaid diagnostic procedures and, in case of
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(Pancreolauryl-test) 11. In all patients the conclusive diagnosis was confirmed by the
clinical follow-up, which included monthly records of symptoms and physical
examination; routine laboratory tests, CA 19-9 assessment, abdominal US and chest
X-ray were performed every three months. A follow-up period of at least 6 months
was required to be included in the study.
’In order to assess the accuracy of the considered diagnostic procedures we
estimated their own sensitivity, specificity and predictive value for cancer: sensitivity
represents the probability that a subject with cancer will give a positive result for
cancer with the test; specificity represents the probability that a subject without
cancer (i.e. chronic pancreatitis) will give a negative result for cancer with the test
and predictive value is the probability that a positive subject will be actually suffering
from cancer. Finally, 95% confidence limits were calculated for sensitivity,
specificity and predictive value1.
RESULTS
Of the 63 patients in the study, 40 (63%) were shown to be affected by pancreatic
adenocarcinoma and 23 (37%) by chronic pancreatitis on the basis of the conclusive
data.
Serum CA 19-9 was over 40 U/ml in 32 patients (80%) with pancreatic arcinoma
and in 5 patients (22%) with chronic pancreatitis.
Abdominal US was positive for neoplasm in 30 patients (75%) with pancreatic
cancer and in 2 patients (9%) with chronic pancreatitis. It was negative for neoplasm
in 15 patients (65%) with chronic pancreatitis and in none of the patients with
pancreatic cancer. It was non-diagnostic in 10 patients (25%) with pancreatic cancer
and in 6 patients (26%) with chronic pancreatitis.
Abdominal CT was positive for neoplasm in 34 patients (85%) with pancreatic
carcinoma and in 1 patient (4%) with chronic pancreatitis. It was negative for
neoplasm in 3 patients (7%) with pancreatic cancer and in 16 patients (70%) with
chronic pancreatitis. It was non-diagnostic in 6 patients (26%) with chronic
pancreatitis and in 3 patients (7%) with pancreatic cancer.
CT- guided pancreatic percutaneous fine-needle biopsy was positive forMTC in all
of the 40 patients with pancreatic cancer (100%) and in none of the patients with
chronic pancreatitis. It was negative forMTC in 20 patients with chronic pancreatitis
(87%). The material was unsuitable for assessment in the remaining 3 patients with
chronic pancreatitis (13%) (Table 1).
Table 1 Results ofserum CA 19-9 assessment, abdominal ultrasound (U.S.), abdominal C.T. scan (C.T.),




Pos. (*) Neg. N.D. Pos. Neg(**) N.D.
CA 19-9 80% 20% 22% 78%
U.S. 75% 0% 25% 9% 65% 26%
C.T. 85% 7% 7% 4% 70% 26%
BIOPSY 100% 0% 0% 0% 87% 13%
Pos.= positive for neoplasm, Neg.= negative for neoplasm, N.D.= non diagnostic.
(*) Sensitivity (**) Specificity312 MICHELE CARLUCCI et al.
In regard of the differential diagnosis between pancreatic cancer and chronic
pancreatitis, sensitivity, specificity and predictive value were respectively 80% 78%
and 86% for serum CA 19-9, 75% 65% and 94% for abdominal US, 85% 70% and
97% for CT scan, 100% 91% and 100% for percutaneous fine-needle biopsy.
95% confidence limits for the four diagnostic procedures were respectively, in case
of sensitivity 64%-90%, 58%-87%, 69%-94%, 94%-100%, in case of specificity
56%-92%, 35%-76%, 40%-79%, 65%-97% and, in case of predictive value 70%-
95%, 78%-99%, 83%-100%, 89%-100% (Figure 1).
In none of the patients did the CT scans done after fine-needle biopsy show
evidence of peri-pancreatic blood clots. There was no significant change in the level
of serum or urinary amylase, nor was there clinical evidence of pancreatitis. Lesions
attributable to percutaneous fine-needle biopsy were never found on surgery, except
for one case where a haemorrhagic collection was present in the greater omentum.
DISCUSSION
The results of our study confirm that it is still difficult to obtain an accurate
differential diagnosis between pancreatic cancer and chronic pancreatitis. In our
experience, as already pointed out by Bodner13, it is easier to make a diagnosis of
malignancy on cytological material than on frozen sections.
We compared the accuracy of serum CA 19-9 assessment, abdominal US, CT
scanning and CT guided pancreatic percutaneous fine-needle biopsy. SerumCA 19-9
proved to be a sensitive and specific tumour marker for pancreatic cancer2’3.
However, its diagnostic reliability is limited by the number of false negative results
3 14 and false positive results in the case of obstructive jaundice’ and active
pancreatitis. The usefulness of serum CA 19-9 assay is more in indicating the
prognosis and as an early marker of relapse in patients who had undergone surgery
for pancreatic cancer15.
There are serious technical limitations with abdominal US, mainly due to the
difficulty in visualising the pancreas if a great amount of intestinal gas is present16.
These limitations were responsible for 10 non-diagnostic cases (25%); sensitivity
(75%) and specificity (65%) are similar to those found in the literature 16’17. In our
experience US would therefore seem to have a limited role in differential diagnosis
between chronic pancreatitis and pancreatic cancer.
The limitation of CT scanning is its frequent inability to distinguish the type of
lesion. However our results cannot prove any statistically significant difference
among the accuracy of serum CA 19-9 assessment, abdominal US and CT scanning
(Figure 1). On the other hand the sensitivity of CT guided pancreatic percutaneous
fine-needle biopsy appeared statistically higher (94%-100%) as compared with the
three previous procedures.
Our experience with pancreatic percutaneous fine-needle biopsy proved very
favourable. The procedure is simple and quick; an average of 1,5 aspirations for each
case were taken, which gradually decreased with the experience of the operator. The
CT guide was able to clearly indicate the blood vessels, the best point for needle
insertion into the lesion and it was unhindered by intestinal gas. This method proved
very reliable in differential diagnosis between pancreatic cancer and chronic
pancreatitis. As far as the specificity is concerned, its results were influenced by 3
inadequate specimens in 3 cases of chronic pancreatitis. The fibrosis often present in
cases of chronic pancreatitis is in fact a limiting factor in obtaining material for aPANCREATIC PERCUTANEOUS FINE-NEEDLE BIOPSY 313
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Figure 95% confidence limits for serum CA 19-9 assessment (CA 19-9), abdominal ultrasound (U.S.),
abdominal C.T. scan (C.T.) and pancreatic percutaneous fine-needle biopsy (biopsy), calculated for
sensitivity, specificity and predictive value.
cytological diagnosis. On the other hand, the finding of numerous inadequate
specimens in different fine-needle biopsies is in our experience suggestive of chronic
pancreatitis.314 MICHELE CARLUCCI et al.
The percutaneous biopsy procedure we used was without immediate complications
such as haemorrhage or pancreatitis. Only in one case there was a mild omental
haemorragic collection, of no clinical significance. This method would seem to be
safe and simple, and the risk of spreading neoplastic cells as reported in the literature
would appear even more remote with increasing expertise in this technique8’18.
In conclusion, CT-guided pancreatic percutaneous fine-needle biopsy was found
to be the most reliable method, in terms of sensitivity, to differentiate pancreatic
cancer by chronic pancreatitis, superior to tumor markers and the non-invasive
techniques such as US and CT scanning. With this method diagnostic explorative
laparotomy can be avoided in selected cases.
Finally, the best diagnostic procedure for a patient with suspected pancreatic
cancer should include initially serumCA 19-9 assessment and abdominal US; if these
procedures are positive or, even if they are negative, and there is a persistent clinical
suspicion of cancer, we think that CT scanning associated with pancreatic
percutaneous fine-needle biopsy is necessary.
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INVITED COMMENTARY
CT-guided fine needle aspiration cytology (FNA) can be extremely helpful in the
diagnosis of pancreatic cancer in patients with focal lesions of the pancreas. No false
negative results were found by Carlucci and co-workers in 40 patients with pancreatic
cancer, proven by surgery or clinical outcome (1). A much lower sensitivity of 68%
91% has been reported in series of more than 25 patients by others using FNA,
guided by CT, Ultrasound (US) or other radiological methods (2). False positive
results of FNA are extremely low, reflecting a specificity of 100% found by most
authors (2,3). Non-diagnostic tests can occur, in as much of 25%, mainly because of
sampling errors (3). These sampling errors had their effect on specificity in the paper
of Carlucci et al. (1) but were treated as a separate catagory by others (3).
The ideal diagnostic test for pancreatic cancer should be accurate, non-invasive,
without complications and cost-effective. Although CT-guided FNA cytology has
some of these characteristics the test is invasive and has complications, such ts
pancreatitis and seeding of tumor along the needle track (4), although the
complications are very infrequent (2). But one individual test can not accurately
make the diagnosis in all patients. And a diagnostic strategy, using different tests
should be used. A strategy can be chosen by decision analysis weighing accuracy,
complication rate and costs of various different strategies as has been clearly
demonstrated by Silverstein et al (5). However, the best diagnostic strategy depends
also on the prevalence of pancreatic cancer and the presenting symptoms in the
group to be studied. Experience of the physicians with the diagnostic, palliative and
curative procedures will also play a role in selection of diagnostic strategy.
Pain and jaundice are the two most frequent clinical symptoms of patients with
pancreatic and periampullary cancer, frequently accompanyed by weight loss.
Resection of pancreatic cancer with hope for cure is practically impossible in non-
jaundiced patients, but can be performed in about 80% of the patients with
obstructive jaundice in a selected group (6). Furthermore biliary drainage should
always be performed in patients with obstructive jaundice, regardless of the chance
of cure. Therefore diagnostic approaches will be different for jaundiced and non-
jaundiced patients.
In non-jaundiced patients with abdominal pain, suspected of pancreatic cancer,
US will be the first step in the diagnostic approach, having a sensitivity of about 70%
(5). The sensitivity can be enhanced to 92.9% when positive findings at US are
combined with elevated serum levels of the tumor markers CA 19-9 and elastase I in
small tumors (7). Others find that serum CA 19-9 is of little help in the diagnosis of
small pancreatic cancers, and may only be useful in the estimation of tumor load
during follow-up (8). Only when US is negative or inadequate a CT-scan is indicated
(5). Tumors shown by US or CT should be evaluated using FNA. ERCP should only
follow when FNA is negative or non diagnostic. The predictive value of a positive
outcome of this strategy is estimated to be more than 99%, regardless of the
prevalence of pancreatic cancer but predictive value of a negative test is estimated to
be high (99%) when prevalence is low (5%) and relatively low (91%) when
prevalence is high (50%). Using this strategy 8.1% of the patients will undergoFNA
in the low prevalence group and 45% in the high prevalence group. Diagnostic
laparotomy can be as low as 1 -6% following these principles (5).
In patients suspected of pancreatic cancer with obstructive jaundice as
predominant presenting clinical symptom, ERCP is the first step of a diagnostic
strategy. US and laboratory tests have usually been performed before to establish the316 MICHELE CARLUCCI et al.
diagnosis of obstructive jaundice. ERCP can have a false positive rate, as low as
5.6%, according to one study (9). An additional advantage ofERCP is that biopsies
of the tumor can be obtained in some cases and the degree of tumor invasion and
obstruction can be appreciated during endoscopy. Furthermore internal biliary
drainage can be achieved by intubation of the tumor with an endoprosthesis (10). In
my opinion this should always be done either as a palliative procedure or as a
preoperative measure as long as no obstruction of the gastro-intestinal tract is
imminent. When curative resection is not taken into consideration because of the
poor general condition or advanced age of the patient excellent non-surgical
palliation is achieved with acceptable mortality, morbidity and re-intervention rate
in very experienced hands (10). For those of us not-experienced in the technique of
endoscopic biliary drainage surgery is still the treatment of choice and palliative
surgery is also indicated for patients with a relatively long life expectancy, since the
chance of serious complications of an endoprosthesis increases over the months. For
these patients that are well enough for curative surgery, preoperative internal biliary
drainage will improve their condition. Drainage can also have a benificial effect on
morbidity and mortality after surgery, probably by leading to a decrease in
endotoxinaemia, as has been shown in experimental studies (11,12). It is most likely
that the complication rate of internal biliary drainage by the endoscopic route is
lower than by the percutaneous transhepatic route (PTD). PTD should be
abandoned for this purpose, since in randomized trials the potential beneficial effect
of preoperative biliary drainage did not outweighed the complications of this
technique (13,14).
At least 2-3 weeks of internal biliary drainage is advised for good results. In that
period further work-up should include dynamic contrast-enhanced CT that can
predit accurately liver metastases and involvement of local large size veins and
arteries (16). Arteriography is thus made superfluous, although ! will still prefer it as
a "roadmap" for surgery. When distant metastases and local irresectability are
diagnosed, FNA cytology of primary tumor or secondaries is useful, especially when
non-surgical palliative treatment is considered. But when laparotomy is going to be
performed anyhow, tissue diagnosis can be obtained at the time of surgery. The
failure rate of preoperative biopsies (16) can probably be improved by the use df
intraoperative US (17).
It can be concluded that FNA cytology of suspected pancreatic lesions is an
essential step in the diagnostic approach of pancreatic cancer with a high predictive
value of a positive test.
By intelligent use of modern diagnostic tests the number of exploratory
laparotomies for pancreatic cancer will be very low (5). Despite the high sensitivity
of CT-guided FNA reported by Carlucci et al. (1) the high percentage of false
negative results in other studies make FNA of limited value in exclusion of cancer
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